In vitro and in vivo effects of treatment by platelet-activating factor on N-formyl-met-leu-phe-mediated responses of polymorphonuclear leucocytes

Abstract

Two chemoattractants, the peptide N-formyl-met-leu-phe (FMLP), and the ether phospholipid, platelet activating factor (PAF), each stimulate a variety of in vitro responses in polymorphonuclear leucocytes (PMN). Because often more than one inflammatory mediator is active during inflammation, we determined the effect on PMN of sequential stimulation with these two agents. Before FMLP stimulation, human PMN were exposed to PAF, at concentrations which gave little or no response when administered alone. PAF enhanced FMLP-elicited superoxide release in a dose-dependent fashion. Likewise, release of granular lysozyme from the cells was increased in PAF treated cells. Similar treatment with other phospholipids, including the lyso derivation of PAF, failed to produce these effects. Incubation with nordihydro-guaiaretic acid, an inhibitor of arachidonic acid metabolism, had little effect on the enhancement of lysozyme release by PAF. To determine if enhancing effects by PAF might occur also in vivo , we studied rabbits receiving PAF and/or FMLP intravenously. When rabbits received 0·01 Μg PAF (a dose which does not elicit the sustained neutropenia observed with higher doses of PAF) followed by 0·05 Μg FMLP the absolute granulocyte count (AGC) dropped at 1 min (46 ± 11% of original value), and continued to fall (24 ± 12% at 10 min). Controls, treated with the suspending fluid for PAF, and then 0·05 Μg FMLP, had a similar 1 min AGC value, but at 10 min AGC returned to 65±6·1% ( P <0·001 for comparison of 10 min values). Thus PAF pretreatment enhanced FMLP-elicited granulocytopenia in vivo . Study of in vitro human PMN aggregation revealed that, at certain relative concentrations of PAF and FMLP. aggregation was enhanced. These studies show that both in vitro and in vivo responses of FMLP-stimulated PMN may be exaggerated by pre-exposure to PAF.